Atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma: The randomised phase III study IMbrave150

被引：0

作者：

Ducreux, M. P. ^{[1
]}

Cheng, A-L. ^{[2
]}

Qin, S. ^{[3
]}

Zhu, A. X. ^{[4
]}

Ikeda, M. ^{[5
]}

Kim, T-Y. ^{[6
]}

Xu, D-Z. ^{[7
]}

Verret, W. ^{[8
]}

Liu, J. ^{[7
]}

Finn, R. S. ^{[9
]}

Galle, P. R. ^{[10
]}

机构：

[1] Gustave Roussy, Med Oncol, Villejuif, France

[2] Natl Taiwan Univ Hosp, Med Oncol, Taipei, Taiwan

[3] Peoples Liberat Army Canc Ctr, Med Oncol, Nanjing, Jiangsu, Peoples R China

[4] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA

[5] Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, Japan

[6] Seoul Natl Univ, Med Oncol, Coll Med, Seoul, South Korea

[7] F Hoffman La Roche Ltd, Roche Prod Dev, Shanghai, Peoples R China

[8] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA

[9] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA

[10] Univ Med Ctr Mainz, Med Dept 1, Mainz, Germany

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

782TiP

引用

页码：267 / 267

页数：1

共 50 条

[31] Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma
Zhang, Xin
Wang, Jingjing
Shi, Juanjuan
Jia, Xiaoli
Dang, Shuangsuo
Wang, Wenjun
JAMA NETWORK OPEN, 2021, 4 (04)
[32] IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC).
Finn, Richard S.
Qin, Shukui
Ikeda, Masafumi
Galle, Peter R.
Ducreux, Michel
Kim, Tae-You
Kudo, Masatoshi
Lim, Ho Yeong
Breder, Valeriy
Merle, Philippe
Kaseb, Ahmed
Li, Daneng
Feng, Yin-Hsun
Verret, Wendy
Nicholas, Alan
Li, Lindong
Ma, Ning
Zhu, Andrew X.
Cheng, Ann-Lii
CANCER RESEARCH, 2021, 81 (13)
[33] IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) 1 bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
Cheng, A-L.
Qin, S.
Ikeda, M.
Galle, P.
Ducreux, M.
Zhu, A.
Kim, T-Y.
Kudo, M.
Breder, V.
Merle, P.
Kaseb, A.
Li, D.
Verret, W.
Xu, Z.
Hernandez, S.
Liu, J.
Huang, C.
Mulla, S.
Lim, H. Y.
Finn, R.
ANNALS OF ONCOLOGY, 2019, 30
[34] IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
Finn, Richard S.
Qin Shukui
Ikeda, Masafumi
Galle, Peter R.
Ducreux, Michel
Kim, Tae-You
Lim, Ho Yeong
Kudo, Masatoshi
Breder, Valeriy Vladimirovich
Merle, Philippe
Kaseb, Ahmed Omar
Li Daneng
Verret, Wendy
Shao Hui
Liu Juan
Li Lindong
Zhu, Andrew X.
Chen, Ann-Lii
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[35] Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial (vol 11, pg 558, 2022)
Li
LIVER CANCER, 2023, 12 (04) : 392 - 393
[36] Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
Margherita Rimini
Mara Persano
Toshifumi Tada
Goki Suda
Shigeo Shimose
Masatoshi Kudo
Jaekyung Cheon
Fabian Finkelmeier
Ho Yeong Lim
José Presa
Gianluca Masi
Changhoon Yoo
Sara Lonardi
Fabio Piscaglia
Takashi Kumada
Naoya Sakamoto
Hideki Iwamoto
Tomoko Aoki
Hong Jae Chon
Vera Himmelsbach
Tiziana Pressiani
Margarida Montes
Caterina Vivaldi
Caterina Soldà
Atsushi Hiraoka
Takuya Sho
Takashi Niizeki
Naoshi Nishida
Christoph Steup
Masashi Hirooka
Kazuya Kariyama
Joji Tani
Masanori Atsukawa
Koichi Takaguchi
Ei Itobayashi
Shinya Fukunishi
Kunihiko Tsuji
Toru Ishikawa
Kazuto Tajiri
Hironori Ochi
Satoshi Yasuda
Hidenori Toyoda
Chikara Ogawa
Takashi Nishimura
Takeshi Hatanaka
Satoru Kakizaki
Noritomo Shimada
Kazuhito Kawata
Fujimasa Tada
Hideko Ohama
Targeted Oncology, 2023, 18 : 221 - 233
[37] IMbrave150: Exploratory efficacy and safety results in patients with hepatocellular carcinoma without macrovascular invasion (MVI) or extrahepatic spread (EHS) treated with atezolizumab (atezo) plus bevacizumab (bev) or sorafenib (sor)
Kudo, M.
Finn, R. S.
Galle, P. R.
Zhu, A.
Ducreux, M. P.
Cheng, A-L.
Verret, W.
Gaillard, V. E.
Nicholas, A.
Lencioni, R.
ANNALS OF ONCOLOGY, 2021, 32 : S818 - S818
[38] Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
Rimini, Margherita
Persano, Mara
Tada, Toshifumi
Suda, Goki
Shimose, Shigeo
Kudo, Masatoshi
Cheon, Jaekyung
Finkelmeier, Fabian
Lim, Ho Yeong
Presa, Jose
Masi, Gianluca
Yoo, Changhoon
Lonardi, Sara
Piscaglia, Fabio
Kumada, Takashi
Sakamoto, Naoya
Iwamoto, Hideki
Aoki, Tomoko
Chon, Hong Jae
Himmelsbach, Vera
Pressiani, Tiziana
Montes, Margarida
Vivaldi, Caterina
Solda, Caterina
Hiraoka, Atsushi
Sho, Takuya
Niizeki, Takashi
Nishida, Naoshi
Steup, Christoph
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
Hatanaka, Takeshi
Kakizaki, Satoru
Shimada, Noritomo
Kawata, Kazuhito
Tada, Fujimasa
Ohama, Hideko
TARGETED ONCOLOGY, 2023, 18 (02) : 221 - 233
[39] Result of atezolizumab plus bevacizumab for advanced or metastatic hepatocellular carcinoma in Vietnamese patients
Hoang, H. T.
ANNALS OF ONCOLOGY, 2024, 35 : S88 - S88
[40] Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma
D'Alessio, Antonio
Cammarota, Antonella
Zanuso, Valentina
Pressiani, Tiziana
Personeni, Nicola
Rimassa, Lorenza
EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (09) : 927 - 939

← 1 2 3 4 5 →